No Detectable Indirect Effects of Late-onset Cytomegalovirus (CMV) Disease after Valganciclovir (VGC) Prophylaxis in Kidney Transplant Recipients.

Lamoth F., Manuel O., Venetz J.-P., Faouzi M., Meylan P., Pascual M.

Infectious Diseases Service, Infectious Diseases Service, Transplantation Centre, Centre of Clinical Epidemiology, Institute of Microbiology

Background: CMV disease remains an important cause of morbidity after kidney transplantation and has been associated with graft loss and other indirect effects. A 3-month course of VGC prophylaxis reduces the incidence of CMV disease. However, little is known about the indirect effects of late-onset CMV disease after VGC prophylaxis.

Objective: To evaluate the impact and indirect consequences of late-onset CMV disease after VGC prophylaxis in kidney transplant recipients.

Methods: Retrospective analysis of 61 consecutive adult kidney transplant recipient with positive CMV serology (donor or recipient) who received VGC prophylaxis for 3 months and completed a follow-up of at least 2 years post-transplantation. Patients who developed CMV disease were compared to CMV disease-free patients for renal function (plasma creatinine values) at 1, 6, 12 and 24 months and for the incidence of graft loss, acute rejection, diabetes, cancer and opportunistic infections.

Results: 8/61 (13%) patients developed CMV disease at a median of 131 days after transplantation (range: 98 – 220). The CMV incidence in D+/R- high risk patients was 6/18 (33%), while it was 2/43 (5%) in intermediate-risk patients (p < 0.01). All 8 patients were treated by oral valganciclovir (median 39 days; range: 19 – 119) with a complete resolution of CMV disease. There was no difference in creatinine values between the two groups at any time during follow-up (Figure). There was no graft loss, and the incidence of acute rejection, cancer and opportunistic infections did not differ between the two group. The incidence of post-transplant diabetes was higher (38% vs 15%) in patients with CMV disease, but this difference was not significant (p = 0.4).

Conclusions: An incidence of 13% of late-onset CMV disease was observed despite 3 months VGC prophylaxis. However, no indirect consequences were found. Moreover, therapy of CMV disease by oral VGC was effective and safe. Larger trials are needed to study whether late-onset CMV disease is associated with indirect consequences, as described with early-onset CMV.

![Graph showing CMV disease-free patients and CMV disease patients](image-url)
Research Day
January 29, 2009
César Roux Auditorium

Genes and Diseases

UNIL | Université de Lausanne
Faculté de biologie
et de médecine
Table des matières

Message du Vice-Doyen de la Recherche de a Faculté de Biologie et de Médecine

Programme

Abstracts

EHU  Environnement Humain  4
ENA  Environnement Naturel  27
GEN  Gènes et Environnement  31
IMI  Immunité et Infection  59
MCV  Métabolisme et Cardiovasculaire  97
NEU  Neurosciences et Psyché  139
ODE  Oncologie et Développement  165
THE  Procédures Thérapeutiques  197

Index des auteurs  215

Couverture : Yannick Krempp, Département de Biologie Cellulaire et de Morphologie – UNIL

Photo : DNA microarray image of an RNA expression profiling experiment provided by Manuela Weier and Henrik Kaessmann of the Centre Intégratif de Génomique - CIG and Jérôme Thomas of the Lausanne DNA Array Facility, Centre Intégratif de Génomique - CIG
Comité d’organisation 2009

Comité scientifique

Jacques Beckmann, Service de Génétique médicale - CHUV
Nouria Hernandez, Centre intégratif de génomique - UNIL
Ivan Stamenkovic, Institut de Pathologie – CHUV
Amalio Telenti, Institut de Microbiologie – CHUV
Gérard Waeber, Service de Médecine interne - CHUV

Poster Jury

Karine Baumer, Institut de Pathologie – CHUV
Dimitri Favre, Service de Médecine interne – CHUV
Marie-Aude Le Bitoux, Institut de Pathologie – CHUV
Erwann Vieu, Centre intégratif de génomique – UNIL

Administration de la Recherche

Jovan Mirkovitch, Faculté de Biologie et de Médecine – CHUV / UNIL
Anne Tricot, Faculté de Biologie et de Médecine - UNIL
Coraline Fraga, Faculté de Biologie et de Médecine - CHUV